AWM
VTGN icon

Atticus Wealth Management’s VistaGen Therapeutics VTGN Stock Holding History

Atticus Wealth Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-23
Closed -$2K – 459
2021
Q2 		$2K Sell
23
-67
-74% -$4.96K ﹤0.01% 354
2021
Q1 		$6K Buy
+90
New +$6.01K ﹤0.01% 307

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Atticus Wealth Management's VTGN Position: Q3 2021 in Review

Atticus Wealth Management sold out of VistaGen Therapeutics (VTGN) in Q3 2021, closing a stake of 23 shares — an estimated $2K sold.

Atticus Wealth Management first reported a position in VTGN in Q1 2021 and held it in 2 quarters. The position peaked at $6K in Q1 2021. 104 funds tracked by Wall St. Rank hold VTGN as of Q3 2021.

  • Atticus Wealth Management reported no remaining VistaGen Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Atticus Wealth Management sold 23 VistaGen Therapeutics shares in Q3 2021, an estimated $2K.
  • Atticus Wealth Management first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 2 quarters.
  • Atticus Wealth Management's VistaGen Therapeutics position peaked at $6K in Q1 2021.
  • 104 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2021.

Based on Atticus Wealth Management's 13F filing for Q3 2021, filed 18 Oct 2021.